Table 5 Multivariate logistic regression models for the outcome variable hospitalization in patients with rheumatoid arthritis and covid-19”
Predictor variables | Initial model | Final model | ||
|---|---|---|---|---|
Adjusted OR (95% CI) | P | Adjusted OR (IC95%CI) | P | |
Age (years) | 1.03 (0.98–1.08) | 0.275 | – | – |
Comorbidities | ||||
No comorbidity | 1.27 (0.19–8.38) | 0.805 | – | – |
Heart disease | 8.65 (1.12–66.54) | 0.038 | 4.61 (1.06–20.02) | 0.041 |
Diabetes mellitus | 1.44 (0.26–7.88) | 0.675 | – | – |
Hypertension | 2.18 (0.61–7.75) | 0.230 | – | – |
Other | 2.3 (0.67–7.83) | 0.185 | – | – |
Symptoms | ||||
Dyspnoae | 7.47 (2.15–25.95) | 0.002 | 6.12 (2.34–16.06) | < 0.001 |
Myalgia | 0.57 (0.17–1.89) | 0.357 | – | – |
Anosmia | 0.24 (0.06–0.92) | 0.037 | 0.26 (0.10–0.67) | 0.005 |
Ageusia | 1.13 (0.23–5.50) | 0.884 | – | – |
Cough | 0.9 (0.27–2.99) | 0.859 | – | – |
Vomits | 4.65 (1.4–15.47) | 0.012 | 4.06 (1.4–11.79) | 0.01 |
Type of confirmatory examination | ||||
RT-PCR (ref. = Not diagnosed) | < 0.001 | < 0.001 | ||
No | 1.96 (0.29–13.35) | 0.490 | 1.46 (0.30–7.14) | 0.644 |
Yes | 26.27 (4.74–145.53) | < 0.001 | 11.54 (3.28–40.59) | < 0.001 |
Drugs | ||||
Anti-TNF | 0.65 (0.13–3.22) | 0.595 | – | – |
Oral corticosteroid (ref. = no use) | 0.005 | 0.016 | ||
< 10 mg/day | 1.44 (0.45–4.6) | 0.538 | 1.89 (0.73–4.94) | 0.192 |
≥ 11 to 20 mg/day | 71.39 (6.79–750.92) | < 0.001 | 20.66 (3.09–138.0) | 0.002 |
≥ 21 mg/day | 6.21 (–) | 0.840 | 2.25 (-) | 0.832 |
bDMARD | 1.38 (0.38–5.01) | 0.626 | ||
Treatment suspension | 1.61 (0.53–4.91) | 0.401 | – | – |
Drugs used to treat COVID-19 | ||||
No drug | 0.2 (0.01–3.64) | 0.277 | – | – |
Azytromycin | 1,88 (0,55—6,49) | 0.317 | – | – |
Oral corticosteroid (ref. = no use) | 0.178 | – | – | |
< 10 mg/day | 7.22 (1.19–43.81) | 0.032 | – | – |
≥ 11 to 20 mg/day | 0.96 (0.19–4.93) | 0.964 | – | – |
≥ 21 mg/day | 0.72 (0.09–5.76) | 0.753 | – | – |
Heparin | 20.58 (3.39–124.81) | 0.001 | 15.89 (4.27–59.11) | < 0.001 |
N | 261 | 261 | ||